History for Cisplatin and Pemetrexed

This web page gives more detail about a specific example discussed in Deriving Chemosensitivity from Cell Lines: Forensic Bioinformatics and Reproducible Research in High-Throughput Biology by Keith A. Baggerly and Kevin R. Coombes. The main page for this paper is here.

One of the case studies involves signatures of response for cisplatin and pemetrexed. This case study was important because these drugs were being used in clinical trials at the time we submitted our paper to the Annals of Applied Statistics. However, this was not the first time we had identified these problems. We communicated with journals involved in 2007 and 2008; at least one of these communicated with Drs. Potti and Nevins at the time -- at least a year and a half before. A full summary is here.

Timeline of Events

Nov 5, 2007: We submit a correspondence and a supplementary report to the Journal of Clinical Oncology (JCO). JCO's acknowledgement of receipt.
Dec 14, 2007: JCO declines our correspondence.
Dec 17, 2007: We ask why.
Jan 4, 2008: JCO declines our correspondence again.
May 30, 2008: We submit a correspondence and figure describing various problems, including those with cisplatin and pemetrexed, to Nature Medicine. Nature Medicine's acknowledgement of receipt.
Jun 2, 2008: Nature Medicine asks permission to share our correspondence with Potti et al., which we grant.
Jun 11, 2008: Nature Medicine declines our correspondence, citing the "detailed response" given by Drs. Potti and Nevins.